Biogen prices new ALS drug at more than $14K per dose

 Biogen has priced its new ALS drug Qalsody at $14,230 per dose, a spokesperson confirmed to Endpoints News on Monday.

Qalsody, also known as tofersen, won an accelerated approval last week for a rare type of ALS marked by a mutation called SOD1. Only about 1% or 2% of ALS patients have the mutation, representing about 300 people in the US, according to Biogen.

https://endpts.com/biogen-prices-new-als-drug-at-more-than-14k-per-dose/